Efficacy and Safety of Experimental versus Approved CAR T-cell Therapies in Large B-cell Lymphoma Using Matching Adjusted Indirect Comparisons: A Systematic Review and Meta-Analysis Protocol
Bayarmagnai Munkhjargal, B. Muresan, S. Solano, A. Macedo, Yoonjung Lee, Gwang-Jin Kim, C. Camargo, Yeseul Ahn, D. Carpenter, Yuchen Su, Gabriela M. Henriquez Luthje
{"title":"Efficacy and Safety of Experimental versus Approved CAR T-cell Therapies in Large B-cell Lymphoma Using Matching Adjusted Indirect Comparisons: A Systematic Review and Meta-Analysis Protocol","authors":"Bayarmagnai Munkhjargal, B. Muresan, S. Solano, A. Macedo, Yoonjung Lee, Gwang-Jin Kim, C. Camargo, Yeseul Ahn, D. Carpenter, Yuchen Su, Gabriela M. Henriquez Luthje","doi":"10.21801/PPCRJ.2021.71.5","DOIUrl":null,"url":null,"abstract":"Background: Relapsed and refractory large B cell lymphomas (RR-LBCL) have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapies have shown considerably high response rates even in RR-LBCL patients who fail to achieve remission after multiple chemotherapy lines. Currently, three CAR T-cell treatments axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (Breyanzi) have been approved for adults with RR-LBCL by regulatory agencies. Non-pivotal clinical trials have independently examined different types of CAR T-cells and have demonstrated remarkable clinical benefit and safety. Yet, no comparison of the experimental and approved CAR T-cells","PeriodicalId":74496,"journal":{"name":"Principles and practice of clinical research (2015)","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Principles and practice of clinical research (2015)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21801/PPCRJ.2021.71.5","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Background: Relapsed and refractory large B cell lymphomas (RR-LBCL) have a poor prognosis. Chimeric antigen receptor (CAR) T-cell therapies have shown considerably high response rates even in RR-LBCL patients who fail to achieve remission after multiple chemotherapy lines. Currently, three CAR T-cell treatments axicabtagene ciloleucel (Yescarta), tisagenlecleucel (Kymriah), and lisocabtagene maraleucel (Breyanzi) have been approved for adults with RR-LBCL by regulatory agencies. Non-pivotal clinical trials have independently examined different types of CAR T-cells and have demonstrated remarkable clinical benefit and safety. Yet, no comparison of the experimental and approved CAR T-cells
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
